Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Hikma Pharmaceuticals PLC - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
HKMPY
Over the counter
2830
www.hikma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Hikma Pharmaceuticals PLC
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
- Jun 8th, 2026 10:30 pm
Generic drugmakers gain key victory in ‘skinny label’ patent case
- Jun 5th, 2026 5:51 am
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma
- Jun 4th, 2026 3:39 pm
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
- Jun 1st, 2026 11:19 am
How The Hikma Pharmaceuticals (LSE:HIK) Narrative Is Shifting After Analyst Valuation Resets
- May 18th, 2026 10:36 pm
Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
- Apr 30th, 2026 6:47 am
Pfizer protects $6.4bn heart disease blockbuster from generics, for now
- Apr 29th, 2026 10:59 am
Pfizer deals extend patent life for a top-selling rare disease drug
- Apr 28th, 2026 6:28 am
Hikma Pharmaceuticals Reiterates 2026 Guidance, Exits 503B Compounding in April Trading Update Call
- Apr 24th, 2026 2:22 am
How The Hikma Pharmaceuticals (LSE:HIK) Narrative Is Shifting With Reset Valuations And Buybacks
- Apr 21st, 2026 6:06 am
How The Investment Story On Hikma Pharmaceuticals (LSE:HIK) Is Shifting With New Targets And News
- Apr 3rd, 2026 11:09 am
How The Hikma Pharmaceuticals (LSE:HIK) Narrative Is Shifting As Analyst Targets Reset
- Mar 20th, 2026 1:07 am
How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge
- Mar 5th, 2026 5:17 am
Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary
- Feb 26th, 2026 2:32 pm
Hikma Pharmaceuticals PLC (HKMPF) Full Year 2025 Earnings Call Highlights: Strong EBITDA ...
- Feb 26th, 2026 10:02 am
Hikma Pharmaceuticals H2 Earnings Call Highlights
- Feb 26th, 2026 2:32 am
Hikma Pharma tumbles on softer guidance as buyback fails to soften pill
- Feb 26th, 2026 1:33 am
What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)
- Feb 6th, 2026 2:08 am
Why Hikma Pharmaceuticals (LSE:HIK) Analysts Are Reframing The Story With New Price Targets
- Jan 22nd, 2026 10:08 pm
Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables
- Jan 12th, 2026 6:00 am
Scroll